Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of PF-07275315 and PF-07264660 in moderate to severe atopic dermatitis
jRCT2051240044Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tilrekimig and ompekimig in atopic dermatitis (AD) (13 arms), sponsored by Pfizer. Primary endpoint: EASI75 at Week 16. Started Nov 2024; status: active, not recruiting.
02
Drugs
tilrekimigompekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2051240044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240044.